As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
Domestic business was up 41.9% YoY and 27.7% QoQ
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Formulation business grew by 15 per cent in the quarter
India business contributes to a stellar performance
Aditya Puri former MD of HDFC bank joins Solara board as chairman
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Subscribe To Our Newsletter & Stay Updated
